Indaptus Therapeutics Stock Operating Margin
| INDP Stock | USD 10.34 0.42 4.23% |
Indaptus Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Indaptus Stock price.
| Last Reported | Projected for Next Year |
Indaptus | Operating Margin | Build AI portfolio with Indaptus Stock |
Indaptus Therapeutics Company Operating Margin Analysis
Indaptus Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Indaptus Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Indaptus Therapeutics is extremely important. It helps to project a fair market value of Indaptus Stock properly, considering its historical fundamentals such as Operating Margin. Since Indaptus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Indaptus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Indaptus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Indaptus Therapeutics has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Indaptus Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Indaptus Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics of similar companies.Indaptus Therapeutics is currently under evaluation in operating margin category among its peers.
Indaptus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Indaptus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Indaptus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Indaptus Fundamentals
| Return On Equity | -2.59 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 1.85 M | ||||
| Shares Outstanding | 572.66 K | ||||
| Shares Owned By Insiders | 36.86 % | ||||
| Shares Owned By Institutions | 13.08 % | ||||
| Number Of Shares Shorted | 14.72 K | ||||
| Price To Book | 2.03 X | ||||
| EBITDA | (15.02 M) | ||||
| Net Income | (15.02 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 84.16 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 4.89 X | ||||
| Cash Flow From Operations | (12.32 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (41.44) X | ||||
| Target Price | 56.0 | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 5.68 M | ||||
| Total Asset | 7.34 M | ||||
| Retained Earnings | (60.44 M) | ||||
| Working Capital | 3.22 M | ||||
| Net Asset | 7.34 M |
About Indaptus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Indaptus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.